Sunday, April 22, 2018

Four dollar drug might be effective against most aggressive prostate cancers

The cell's mitochondria produce the energy that fuels the
cell. Metformin may be used to shut down mitochondria
in aggressive prostate cancer cells 
CANCER DIGEST – April 22, 2018 – New research shows how a common drug for diabetes may halt aggressive prostate cancer.

The drug metformin has long been linked with anti-cancer properties as numerous studies have shown lower rates of certain cancers among diabetic patients who take the drug, but just how the drug might work against cancer was unknown.

Saturday, April 14, 2018

Double-drug strategy blocks escape route for most lung cancers

The tumors in the top three rows above were treated with
 current drugs, the bottom row tumors were treated with the
new combination. Image courtesy of UT Southwestern
CANCER DIGEST – April 14, 2018 – A combination of two, already FDA-approved drugs, appear to be effective in treating non-small lung cancer, at least in mice models that had human-derived tumors, researchers say. Because the two drugs are already approved, the researchers hope to have a clinical trial in humans approved within a year.

The two drugs include a class of drugs called EGFR inhibitors such as Erbitux®, Tarceva® and Iressa®, and the class of TNF inhibitors such as Humira®, Enbrel® and Remicade®.

Sunday, April 8, 2018

New combination shows promise in advanced lung cancer

CANCER DIGEST – April 8, 2018 – A new combination therapy of using an immunotherapy drug, with a new and powerful immune stimulation drug, shows promise in patients whose advanced lung cancer has become resistant to other therapies, preliminary results of a clinical trial shows.

The study is the first time the immune stimulant has been combined with one of the new class of drugs, called checkpoint drugs such as nivolumab (OPDIVO®) and pembrolizumab (Keytruda) according to study leaders Drs. John Wrangle, and Mark Rubinstein, PhD., of the Hollings Cancer Center at the Medical University of South Carolina.

Saturday, March 17, 2018

Medicare will cover genetic tests for cancer patients

CANCER DIGEST – Mar. 17, 2018 – The Centers for Medicare & Medicaid Services (CMS) announced on Mar. 16 that Medicare will cover genetic testing needed to match cancer patients with targeted immunotherapies. Specifically Medicare will cover Next Generation Sequencing (NGS) for patients with advanced cancer that has spread or has relapsed or fails to respond to other therapies.

Saturday, March 10, 2018

UK’s National Health Service to trial mpMRI for prostate cancer

Patient being positioned for an MRI – image used under
Creative Commons share alike license from Wikipedia
CANCER DIGEST – March 10, 2018 –In an effort to improve and speed up prostate cancer diagnosis, Britain’s National Health Service has launched a trial of a "one-stop" service in three west London hospitals. The goal is to complete all the tests needed to tell a man whether or not he has prostate cancer in one day.

Saturday, February 24, 2018

Trojan Horse targets metastatic cancer

Image credit: Pellecchia Lab, UC Riverside
CANCER DIGEST – Feb. 24, 2018 – Researchers have developed a Trojan Horse that delivers anti-cancer drug to a metastatic cancer cell. If proven successful, it could be used to reduce or halt metastases, which is the leading cause of death in cancer.

Once cancer metastasizes, or spreads to other parts of the body, there is no current therapy that can target those traveling cancer cells, and chemotherapy is indiscriminate, destroying healthy as well as cancerous cells.

Saturday, February 17, 2018

Accuracy of tests for predicting breast cancer recurrence vary significantly

Image courtesy Queen Mary
University of London
CANCER DIGEST – Feb. 17, 2018 – Tests used to predict breast cancer recurrence vary significantly in accuracy according to the first side-by-side comparison of the four most common tests.

In a study published in the Feb. 15, 2018 journal JAMA Oncology researchers led by Ivana Sestak, PhD of the Centre for Cancer Prevention at Queen Mary University of London, compared the predictive performance of the four most widely used biomarker analysis tests: Oncotype DX, PAM50, Breast Cancer Index (BCI) and the EndoPredict (EPclin), which all work by looking at the levels of multiple genes related to breast cancer.

Saturday, February 10, 2018

Imaging-first strategy effective for prostate cancer


CANCER DIGEST – Feb. 9, 2018 – An advanced imaging technique is a cost-effective first test for the diagnosis of prostate cancer when followed by a combination imaging-guided biopsy say researchers.

The PROMIS study published in the January 2018 European Urology was designed to compare cost and effectiveness of three diagnostic strategies: transrectal ultrasound-guided biopsy (TRUSB), template prostate mapping biopsy (TPMB), and multiparametric magnetic resonance imaging (mpMRI) for the detection of clinically significant prostate cancer.

Friday, January 19, 2018

Another blood test for cancer shows promise


CANCER DIGEST – Jan. 19, 2018 – A team of researchers have developed another blood test for cancer, which if confirmed in clinical trials, could identify eight cancer types from a single blood draw.

The team at Johns Hopkins University of School of Medicine published its findings in the Jan. 18, 2018 journal Science. The test, called CancerSEEK simultaneously evaluates the levels of eight cancer proteins and the presence of cancer gene mutations from circulating DNA in the blood. Five of the cancers currently have no screening test.

Saturday, January 13, 2018

New test predicts age of onset of aggressive prostate cancer

CANCER DIGEST – Jan. 13, 2018 – A new test based on genomic research combined with population research is able to predict the age of onset of aggressive prostate cancer, researchers say.

The tool is based on searches of individual genomes, the entire set of genes that make up an individual, for small variations, called single-nucleotide polymorphisms or SNPs that occur more frequently in people with a particular disease compared to people without the disease.